These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38263981)

  • 1. Unlocking antitumor immunity with adenosine receptor blockers.
    Remley VA; Linden J; Bauer TW; Dimastromatteo J
    Cancer Drug Resist; 2023; 6(4):748-767. PubMed ID: 38263981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8
    Chen S; Akdemir I; Fan J; Linden J; Zhang B; Cekic C
    Cancer Immunol Res; 2020 Aug; 8(8):1064-1074. PubMed ID: 32381524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
    Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
    Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
    Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis.
    Huang T; Ren X; Tang X; Wang Y; Ji R; Guo Q; Ma Q; Zheng Y; Hu Z; Zhou Y
    Front Immunol; 2024; 15():1427380. PubMed ID: 39188712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
    Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cekic C; Day YJ; Sag D; Linden J
    Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts.
    Chen Y; Epperson S; Makhsudova L; Ito B; Suarez J; Dillmann W; Villarreal F
    Am J Physiol Heart Circ Physiol; 2004 Dec; 287(6):H2478-86. PubMed ID: 15284071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
    Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
    Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
    Young A; Ngiow SF; Gao Y; Patch AM; Barkauskas DS; Messaoudene M; Lin G; Coudert JD; Stannard KA; Zitvogel L; Degli-Esposti MA; Vivier E; Waddell N; Linden J; Huntington ND; Souza-Fonseca-Guimaraes F; Smyth MJ
    Cancer Res; 2018 Feb; 78(4):1003-1016. PubMed ID: 29229601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD39/CD73/A2AR pathway and cancer immunotherapy.
    Xia C; Yin S; To KKW; Fu L
    Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.
    Leone RD; Lo YC; Powell JD
    Comput Struct Biotechnol J; 2015; 13():265-72. PubMed ID: 25941561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine A
    Yu F; Zhu C; Xie Q; Wang Y
    J Med Chem; 2020 Nov; 63(21):12196-12212. PubMed ID: 32667814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A
    Dziedzic K; Węgrzyn P; Gałęzowski M; Bońkowska M; Grycuk K; Satała G; Wiatrowska K; Wiklik K; Brzózka K; Nowak M
    Int Immunopharmacol; 2021 Jul; 96():107645. PubMed ID: 33894488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
    Bao X; Xie L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
    Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway.
    Li N; Tang N; Cheng C; Hu T; Wei X; Han W; Wang H
    Oncoimmunology; 2020 Sep; 9(1):1824643. PubMed ID: 33457103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.